-+ 0.00%
-+ 0.00%
-+ 0.00%
BridgeBio's acoramidis cuts risk of first heart failure event by 45% versus placebo in trial
Share
Listen to the news
BridgeBio's acoramidis cuts risk of first heart failure event by 45% versus placebo in trial
  • BridgeBio Pharma announced Nov. 17, 2026, that real-world evidence linked acoramidis to less worsening heart failure than tafamidis in ATTR-CM.
  • Results were presented at the 2026 American Heart Association Scientific Sessions and International Symposium on Amyloidosis.
  • Phase 3 ATTRibute-CM findings showed fewer heart failure events versus placebo, with benefits emerging within the first month.
  • Continuous treatment was associated with lower heart failure mortality through 54 months compared with delayed initiation.
  • Kidney analyses found no clinically meaningful safety changes accompanying an early kidney-function dip; function remained stable in participants with advanced kidney disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170730PRIMZONEFULLFEED9879120) on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending